Acadia Pharmaceuticals has resubmitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of Nuplazid (pimavanserin) for hallucinations and delusions associated with psychosis in Alzheimer’s disease. The announcement from Acadia comes less than a year after the FDA rejected the company’s original application for Nuplazid to treat the broader category of dementia-related psychosis. In its response, the FDA did not note any safety issues related to Nuplazid, but raised concerns related to…
You must be logged in to read/download the full post.
The post Nuplazid Resubmitted for FDA Approval for Psychosis in Alzheimer’s appeared first on BioNewsFeeds.